PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Abstract 190: Breast cancer liver metastasis: Primary tumor predictors and histopathologic characteristics of metastatic lesions.

View Full Paper
HCHatun Duran CeteABAlexandra Q. BartlettMOMichelle Kayoko Ozaki

Key Points

  • The study aims to identify predictors of liver metastasis in breast cancer and analyze the histopathologic characteristics of those lesions.
  • Collected BCLM tissue samples from 47 breast cancer patients via biopsy or surgical resection.
  • Analyzed clinicopathological characteristics at primary diagnosis to find links to liver metastasis.
  • Conducted histological and immunohistological analyses on BCLM tissues to assess tumor characteristics.
  • 38% of patients were aged 45 or younger at primary diagnosis, often related to childbirth.
  • 85% of primary tumors were estrogen receptor positive, with 60% categorized as luminal A.
  • Dominant replacement growth pattern observed in 87% of liver metastases, utilizing liver architecture.

Abstract

Abstract Background: Breast cancer metastasis to the liver (BCLM) has poor outcomes because predicting patients at risk for liver metastasis remains elusive as does effective targeting of metastatic lesions. Known risk factors for BCLM include young patient age and primary breast cancer diagnoses of high grade, late stage and triple negative or HER2+ subtypes. Prognostic sensitivity is currently low. Further, lack of histopathologic characterization of BCLM tumors in the literature limits development of targeted therapeutics. Methods: We collected retrospective and prospective BCLM tissues from forty-seven breast cancer patients who underwent liver biopsy (87%) or surgical resection (13%) for clinical indications of BCLM at OHSU Portland, Oregon. Patients were enrolled regardless of age or breast cancer subtype. Patient clinicopathological characteristics at time of primary breast cancer diagnosis were used to identify breast cancer attributes associated with liver metastasis. Histological and immunohistology analyses of formalin fixed paraffin (FFPE) embedded BCLM tissues were employed to assess metastatic tumor and tumor niche characteristics within the liver. Results: At primary breast cancer diagnosis, 38% of cases were ≤45 years of age, with 72% of these young cases diagnosed within 10 years of childbirth. Regardless of patient age, 85% of the primary cancers were ER+, 60% luminal A, 57% low grade, and 73% early stage. The majority of the BCLM lesions were also ER+, while ∼10% of the ER+ primary lesions converted to ER- in metastasis. Progesterone receptor switching from ER+PR+ primary to ER+PR- BCLM occurred in ∼50% of ER+PR+ cases. High GATA3 staining was observed in 86% of the BCLM tumors, supporting luminal breast cell origin. Replacement growth pattern was dominant, observed in 87% of cases, with immunohistology and immunofluorescence evidence that breast tumor cells utilize existing sinusoidal architecture to establish and maintain metastatic outgrowth. Conclusions: In our single institution cohort, we find that recent pregnancy, young age and proximity to recent childbirth are associated with breast cancer metastasis to the liver. We found most primary cancers that progressed to liver metastasis were ER positive, luminal A, low-grade and early-stage, suggesting these classically-good prognostic indicators in breast cancer may not remain good indicators when accompanied by metastasis to the liver. Finally, improved understanding of the dominant replacement growth pattern and the relation between tumor cells and the liver sinusoids may lead to new drug targets and precision therapies. Citation Format: Hatun Duran Cete, Alexandra Bartlett, Michelle Kayoko Ozaki, Jackie Phipps, Pepper Schedin. Breast cancer liver metastasis: Primary tumor predictors and histopathologic characteristics of metastatic lesions abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 190.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Cete et al. (2026) studied this question.

synapsesocial.com/papers/69d1fcfda79560c99a0a2d15https://doi.org/10.1158/1538-7445.am2026-190
Ask AI
Helpful
Bookmark
Share
View Full Paper